GlassScriptPhysician profile
Mustafa Aladin
NPI 1538546791
$3,284.23
in general payments reported to CMS, 2019-2025
32 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $246 · 2021: $693 · 2022: $742 · 2023: $374 · 2024: $412 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.65 |
| Education | $145.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $579.33 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $497.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Nestle Healthcare Nutrition INC. | $273.77 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $263.90 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Kowa Pharmaceuticals America, INC. | $181.97 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $168.44 | 2019-2024 | Mounjaro, Zepbound |
| Allergan, INC. | $124.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.73 | 2020-2025 | Xifaxan |
| Medtronic, INC. | $103.99 | 2021-2022 | |
| Gilead Sciences, INC. | $101.82 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $98.98 | 2021-2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.19 | 2020-2022 | |
| Amgen INC. | $79.74 | 2021-2023 | Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $69.53 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Pfizer INC. | $66.70 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $56.04 | 2021-2022 | |
| Astellas Pharma US INC | $55.50 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $50.27 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.50 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $46.33 | 2019-2021 | |
| Abbott Laboratories | $28.08 | 2022 | |
| Sobi, INC | $23.89 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $23.09 | 2025 | Austedo Xr |
| Exact Sciences Corporation | $17.53 | 2025 | The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $17.33 | 2021 | |
| Dexcom, INC. | $16.16 | 2021 | |
| Hologic Sales and Service, LLC | $14.97 | 2024 | Aptima |
| Cmp Pharma, INC. | $14.74 | 2021 | |
| Azurity Pharmaceuticals, INC. | $13.93 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.80 | 2021 | |
| Organon LLC | $13.20 | 2021 | |
| Glaxosmithkline, LLC. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mustafa Aladin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.